BioNTech SE
BNTX
$87.95
$0.740.85%
| 12/31/2023 | 09/30/2023 | 06/30/2023 | 03/31/2023 | 12/31/2022 | |
|---|---|---|---|---|---|
| Revenue | 4.12B | 6.90B | 9.41B | 12.63B | 18.42B |
| Total Other Revenue | -- | -- | -- | -- | -- |
| Total Revenue | 4.12B | 6.90B | 9.41B | 12.63B | 18.42B |
| Cost of Revenue | 649.19M | 643.87M | 1.23B | 1.86B | 3.21B |
| Gross Profit | 3.47B | 6.25B | 8.18B | 10.77B | 15.21B |
| SG&A Expenses | 603.42M | 604.77M | 586.79M | 590.95M | 567.80M |
| Depreciation & Amortization | -- | -- | -- | -- | -- |
| Other Operating Expenses | -98.43M | -314.04M | -13.06M | 210.17M | 338.05M |
| Total Operating Expenses | 3.08B | 2.76B | 3.43B | 4.31B | 5.73B |
| Operating Income | 1.04B | 4.14B | 5.98B | 8.32B | 12.69B |
| Income Before Tax | 1.27B | 3.80B | 6.01B | 8.93B | 13.81B |
| Income Tax Expenses | 272.68M | 965.00M | 1.56B | 2.49B | 3.75B |
| Earnings from Continuing Operations | 999.08 | 2.83K | 4.46K | 6.45K | 10.06K |
| Earnings from Discontinued Operations | -- | -- | -- | -- | -- |
| Extraordinary Item & Accounting Change | -- | -- | -- | -- | -- |
| Minority Interest in Earnings | -- | -- | -- | -- | -- |
| Net Income | 999.08M | 2.83B | 4.46B | 6.45B | 10.06B |
| EBIT | 1.04B | 4.14B | 5.98B | 8.32B | 12.69B |
| EBITDA | 1.19B | 4.27B | 6.10B | 8.44B | 12.81B |
| EPS Basic | 4.15 | 11.67 | 18.43 | 26.60 | 41.36 |
| Normalized Basic EPS | 3.37 | 9.78 | 15.54 | 23.04 | 35.49 |
| EPS Diluted | 4.11 | 11.53 | 17.84 | 25.57 | 39.35 |
| Normalized Diluted EPS | 3.35 | 9.66 | 15.03 | 22.15 | 33.77 |
| Average Basic Shares Outstanding | 963.06M | 966.25M | 966.78M | 969.50M | 971.36M |
| Average Diluted Shares Outstanding | 966.69M | 971.77M | 987.78M | 1.01B | 1.02B |
| Dividend Per Share | -- | -- | -- | -- | -- |
| Payout Ratio | -- | -- | -- | 8.00% | 5.13% |
